Current Status and Future Direction of Immune Checkpoint Inhibitors
-
- Kagamu Hiroshi
- Department of Respiratory Medicine, Saitama Medical University International Medical Center
Bibliographic Information
- Other Title
-
- 免疫チェックポイント阻害薬の現状と展望
Search this article
Abstract
<p>In contrast to therapies such as chemotherapy and targeted therapy, immune checkpoint inhibitors (ICIs) targeting PD-1 or CTLA-4 significantly improve the durable response rate and achieve a long-term survival. While chemotherapy and targeted therapy induce tumor shrinkage and prolong the survival, they cannot overcome naturally occurring resistance mechanisms induced by the accumulation of mutations, as Goldie and Coldman predicted. ICIs restore host antitumor T cell immunity, which recognizes neoantigens and destroys cancer cells carrying a high number of mutations. PD-1 plays a central role in suppressing T cell immunity, so PD-1 blockade remains a fundamental therapy. Combination therapy with PD-1 blockade and other treatments, such as chemotherapy, radiotherapy, surgery, and new ICIs, to obtain synergistic effects and increase the rate of long-term survival has begun to gain traction. The identification of biomarkers underlying antitumor T cell immunity mechanisms will optimize ICI therapy.</p>
Journal
-
- Haigan
-
Haigan 59 (3), 217-223, 2019-06-20
The Japan Lung Cancer Society
- Tweet
Details 詳細情報について
-
- CRID
- 1390282763126308224
-
- NII Article ID
- 130007674423
-
- ISSN
- 13489992
- 03869628
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed